A new report highlights some positive news from a pharma employment point of view.

Biosimilars may not be the only business Merck KGaA divests in 2017.

Kite Pharma's ability to handle the complex manufacturing of its CAR-T cancer treatment is one reason Gilead is paying $11.9 billion for the company.

Did Daiichi Sankyo receive a buyout bid from AstraZeneca last year? According to the Japanese drugmaker, no.

The Big Pharma workforce in 2007 appears remarkably similar to the present. Underneath those numbers, though, are some major shifts.

Teva is working to sell off its women’s health unit to churn up cash and pay down debt, and it may have some takers.

Fosun Pharma and Shanghai Pharma are bidding for a stake in U.S. drugmaker Arbor Pharma.

The generics pricing hit that's slammed Teva shares over last week? The company knew it was coming—and stayed mum for five weeks.